尼达尼布联合培美曲塞和顺铂用于化疗初治的晚期恶性胸膜间皮瘤患者(LUME-Meso):一项双盲、随机、安慰剂对照3期试验
LUME-Meso 3期部分在全球27个国家120个学术医疗中心和社区诊所开展,纳入458例不可切除上皮样恶性胸膜间皮瘤、ECOG 0-1、化疗初治成人患者,1:1随机接受最多6个21天周期的培美曲塞(500 mg/m2)加顺铂(75 mg/m2)第1天,随后尼达尼布(200 mg每日两次)或匹配安慰剂第2-21天,无进展者接受维持治疗。主要终点意向治疗人群的无进展生存期在尼达尼布组(中位6.8个月,95%CI 6.1-7.0)与安慰剂组(7.0个月,95%CI 6.7-7.2)间无差异(HR 1.01,95%CI 0.79-1.30,p=0.91)。3级及以上不良事件最常见为中性粒细胞减少(尼达尼布组73例[32%] vs 安慰剂组54例[24%]),严重不良事件分别为99例(44%)和89例(39%),唯一在任一组发生率≥5%的严重不良事件为肺栓塞(13例[6%] vs 7例[3%])。3期主要终点未达到,2期发现未获证实,未报告非预期安全性发现。
要点
- 尼达尼布组中位无进展生存期6.8个月(95%CI 6.1-7.0)vs 安慰剂组7.0个月(95%CI 6.7-7.2),HR 1.01(95%CI 0.79-1.30),p=0.91,无差异。
- 3级及以上中性粒细胞减少:尼达尼布组73例(32%)vs 安慰剂组54例(24%)。
- 严重不良事件:尼达尼布组99例(44%)vs 安慰剂组89例(39%);肺栓塞13例(6%)vs 7例(3%)。
- 尼达尼布组中位治疗时长5.3个月(IQR 2.8-7.3),安慰剂组5.1个月(IQR 2.7-7.8)。
- 3期主要终点未达到,2期发现未获证实,未报告非预期安全性发现。
适用人群与场景
- 化疗初治的成人(年龄≥18岁)不可切除上皮样恶性胸膜间皮瘤患者,ECOG体能状态0-1。
处置流程与药物剂量
- 培美曲塞500 mg/m2加顺铂75 mg/m2第1天,每21天一个周期,最多6个周期;尼达尼布200 mg每日两次或匹配安慰剂在第2-21天给药。
- 6个周期后无疾病进展的患者接受尼达尼布或安慰剂维持治疗,每周期第1-21天给药。
研究设计与关键结果
- 研究类型:双盲、随机、安慰剂对照3期试验,在27个国家120个学术医疗中心和社区诊所开展,458例患者随机分配至尼达尼布组(n=229)或安慰剂组(n=229)。
- 主要终点:意向治疗人群的无进展生存期,尼达尼布组中位6.8个月(95%CI 6.1-7.0)vs 安慰剂组7.0个月(95%CI 6.7-7.2),HR 1.01(95%CI 0.79-1.30),p=0.91,无差异。
- 安全性:3级及以上不良事件最常见为中性粒细胞减少,尼达尼布组73例(32%)vs 安慰剂组54例(24%);严重不良事件尼达尼布组99例(44%)vs 安慰剂组89例(39%);唯一在任一组发生率≥5%的严重不良事件为肺栓塞,尼达尼布组13例(6%)vs 安慰剂组7例(3%)。
证据类型、等级与局限
- 证据类型:随机对照试验(3期)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为3期主要终点无进展生存期未达到,2期发现未获证实,未报告非预期安全性发现。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Nintedanib targets VEGF receptors 1-3, PDGF receptors α and β, FGF receptors 1-3, and Src and Abl kinases, which are all implicated in malignant pleural mesothelioma pathogenesis. Here, we report the final results of the phase 3 part of the LUME-Meso trial, which aimed to investigate the efficacy and safety of pemetrexed plus cisplatin combined with nintedanib or placebo in unresectable malignant pleural mesothelioma.
METHODS: This double-blind, randomised, placebo-controlled phase 3 trial was done at 120 academic medical centres and community clinics in 27 countries across the world. Chemotherapy-naive adults (aged ≥18 years) with unresectable epithelioid malignant pleural mesothelioma and ECOG performance status 0-1 were randomly assigned 1:1 via an independently verified random number-generating system to receive up to six 21-day cycles of pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on day 1, then nintedanib (200 mg twice daily) or matched placebo on days 2-21. Patients without disease progression after six cycles received nintedanib or placebo maintenance on days 1-21 of each cycle. The primary endpoint was progression-free survival (investigator-assessed according to mRECIST) in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of their assigned study drug. This study is registered with ClinicalTrials.gov, number NCT01907100.
FINDINGS: Between April 14, 2016, and Jan 5, 2018, 541 patients were screened and 458 were randomly assigned to either the nintedanib group (n=229) or the placebo group (n=229). Median treatment duration was 5·3 months (IQR 2·8-7·3) in the nintedanib group and 5·1 months (2·7-7·8) in the placebo group. After 250 events, progression-free survival was not different between the nintedanib group (median 6·8 months [95% CI 6·1-7·0]) and the placebo group (7·0 months [6·7-7·2]; HR 1·01 [95% CI 0·79-1·30], p=0·91). The most frequently reported grade 3 or worse adverse event in both treatment groups was neutropenia (73 [32%] in the nintedanib group vs 54 [24%] in the placebo group). Serious adverse events were reported in 99 (44%) patients in the nintedanib group and 89 (39%) patients in the placebo group. The only serious adverse event occurring in at least 5% of patients in either group was pulmonary embolism (13 [6%] vs seven [3%]).
INTERPRETATION: The primary progression-free survival endpoint of the phase 3 part of LUME-Meso was not met and phase 2 findings were not confirmed. No unexpected safety findings were reported.
FUNDING: Boehringer Ingelheim.
参考来源
- Scagliotti GV, Gaafar R, Nowak AK, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2019. PMID: 31103412. doi:10.1016/S2213-2600(19)30139-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。